NASDAQ:PHAT
Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc.'s revenue grew 216.9% in fiscal 2025 to $175.1M while operating margin rose to −91.4%, its highest in 3 years. Free cash flow was −$167.0M, −95.4% of revenue, and the diluted share count rose 15.4%.Summary generated from Phathom Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$175.1M
Revenue growth+216.9%
Revenue, 5-yr CAGRn/a
Gross margin87.1%
Operating margin−91.4%
Net margin−126.3%
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow−$167.0M
FCF margin−95.4%
Share count change+15.4%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | 0 | 1 | 55 | 175 |
| Operating income | −135 | −172 | −167 | −277 | −160 |
| Net income | −144 | −198 | −202 | −334 | −221 |
| Free cash flow | −149 | −148 | −139 | −267 | −167 |
Recent filings
- 4Insider transaction report
Oct 8, 2026 - 8-KOther events
Sep 29, 2026 - 4Insider transaction report
Sep 8, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 30, 2026 - 8-KResults of operations and financial condition
Jul 30, 2026 - 8-KOther events
Jun 23, 2026 - 8-KResults of a shareholder vote
May 21, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
Apr 30, 2026